Immune thrombocytopenia (ITP) is an autoimmune disease characterized by autoantibody-mediated platelet destruction. Treatment with CM313, a novel anti-CD38 monoclonal antibody, can result in targeted ...

Heparin-induced thrombocytopenia (HIT) is an immune-mediated adverse reaction to heparin characterised by a paradoxical combination of thrombocytopenia and an elevated risk of thrombosis. Central to ...

A panelist discusses how immune thrombocytopenia (ITP) is characterized by isolated low platelet counts due to autoimmune destruction, with classification based on duration (acute, extended, or ...

Current second-line treatments for immune thrombocytopenia (ITP) require long-term administration. Ianalumab, a monoclonal antibody targeting B cells, is being assessed as a short-course second-line ...